Healthcare Services

Liquid Biopsy Market Insights Highlighting Opportunities and Drivers Supporting Growth to 2030

April 2, 2026April 15, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Liquid Biopsy Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The liquid biopsy market size has experienced rapid growth in recent years. It is projected to expand from $1.46 billion in 2025 to $1.71 billion in 2026, at a compound annual growth rate (CAGR) of 17.3%. The market’s historical growth can be attributed to several factors including the limitations inherent in traditional tissue biopsy procedures, the rising global incidence of cancer, the early adoption of blood-based diagnostic methods, progress in molecular biology techniques, and a heightened focus on early cancer diagnosis.

The liquid biopsy market size is projected to experience swift expansion over the coming years. This market is anticipated to reach a valuation of $3.11 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.2%. The projected increase throughout this period stems from several factors, including a heightened need for precision oncology, greater implementation in routine cancer screenings, broadening uses in recurrence tracking, increased expenditure on oncology diagnostics, and improved understanding among healthcare professionals and patients. Key developments expected during the forecast period encompass a surging embrace of non-invasive methods for cancer diagnosis, more frequent deployment of liquid biopsy for detecting cancer early, an escalating requirement for continuous treatment assessment, the expansion of liquid biopsy within personalized oncology, and a growing clinical acknowledgment as a substitute for tissue biopsy.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2815&type=smp

What Key Drivers Are Influencing The Growth Of The Liquid Biopsy Market?

Elevated government financial support for advancing cancer detection is a key driver in the growth of the liquid biopsy market. This funding is primarily attributed to the increasing worldwide burden of cancer, the imperative for early diagnosis to improve treatment outcomes, and the focus on reducing healthcare costs through innovative diagnostic technologies. Governmental investment aids liquid biopsy by expediting research and development, supporting clinical trials, and promoting the adoption of advanced, non-invasive diagnostic tools, thereby enhancing early cancer identification and personalized treatment strategies. For instance, in October 2024, gov.UK, a UK-based government website, announced an allocation of £118 ($150.38) million to UK Research and Innovation, comprising £54 million from the government and £64 ($81.55) million from partners. Consequently, the augmented government funding for improving cancer detection is propelling the expansion of the liquid biopsy market.

What Major Segment Divisions Exist Within The Liquid Biopsy Market?

The liquid biopsy market covered in this report is segmented –

1) By Product: Assay Kits, Instruments, Services

2) By Clinical Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring

3) By End User: Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers

Subsegments:

1) By Assay Kits: cfDNA Assays, ctDNA Assays, Exosome-based Assays, RNA-based Assays

2) By Instruments: PCR Instruments, Next-Generation Sequencing (NGS) Instruments, Microarray Instruments

3) By Services: Testing Services, Data Analysis Services, Laboratory Services

What Key Developments And Trends Are Impacting The Liquid Biopsy Market?

Leading companies within the liquid biopsy market are concentrating on developing innovative solutions, such as comprehensive circulating tumor DNA (ctDNA) genomic-profiling assays. These advancements aim to accelerate noninvasive cancer profiling, facilitate quicker therapeutic decision-making, and broaden access to precision oncology, particularly where tissue samples are limited or unobtainable. A comprehensive ctDNA genomic-profiling assay functions by analyzing fragments of tumor-derived cell-free DNA in the bloodstream to identify somatic small variants, copy-number changes, insertions/deletions, and immuno-oncology signatures (e.g., bTMB and bMSI). This offers extensive tumor insight without the invasiveness, potential sampling bias, and extended turnaround times associated with traditional tissue biopsies. For example, in November 2023, Illumina Inc., a US-based sequencing and genomics company, launched TruSight Oncology 500 ctDNA v2, a research-use liquid biopsy panel designed for noninvasive genomic profiling of solid tumors. This panel integrates an expanded hybrid-capture panel with DRAGEN bioinformatics, enabling the sequencing of 523 biomarkers from low cfDNA input. The assay effectively enriches and detects SVs, CNVs, indels, and immuno-oncology metrics with high analytical performance, provides streamlined workflows involving a single hybridization step and a turnaround time of less than 4 days, and is compatible with NovaSeq systems and upcoming automation. It proves useful when tissue is unavailable or delayed, complements tissue testing, and supports broad pan-cancer research and trial screening, delivering faster insights, suitability for low-input samples, and easier adoption across distributed lab environments.

Which Companies Are Leading Innovation In The Liquid Biopsy Market?

Major companies operating in the liquid biopsy market are QIAGEN NV, Roche Diagnostics Ltd., Bio-Rad Laboratories Inc., Myriad Genetics Inc., Guardant Health Inc., Thermo Fisher Scientific Inc., Biocept Inc., Trovagene Inc., Fraunhofer-Gesellschaft, MDX Health SA, Agilent Technologies Inc., Illumina Inc., Oxford Nanopore Technologies Ltd., Quantum Biosystems Inc., Menarini Silicon Biosystems Inc., Pathway Genomics Corporation, Sysmex Corporation, Janssen Global Services LLC, Natera Inc., ANGLE Plc, Bio Techne Corp, Biodesix Inc., CellMax Inc., CIRCULOGENE, Exact Sciences Corporation, Epic Sciences Inc., Exosome Diagnostics Inc., GRAIL Inc., Inivata Ltd., NIPD Genetics, Oncocyte Corporation, Personal Genome Diagnostics Inc., RainDance Technologies Inc., Thrive Earlier Detection Corp.

Read the full liquid biopsy market report here:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Liquid Biopsy Market?

North America was the largest region in the liquid biopsy market in 2025. Western Europe was the second largest region in the liquid biopsy market. The regions covered in the liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Liquid Biopsy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2815&type=smp

Browse Through More Reports Similar to the Global Liquid Biopsy Market 2026, By The Business Research Company

Liquid Biopsy Global Market Report

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Biopsy Devices Global Market Report

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Cancer Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795